Table VI.
APC Adoptive Transfer Reduces Th2 Cell Capacity to Polarize Immunity Post-BMT.
| Transplant Componentsb |
Post-BMT Cytokine Productione |
p-valuesf |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cohort # | Host Tumora | BM | T Cells | Th2 Cells | Donor DCc | Host DCd | IL-2 | IFN-γ | IL-4 | IL-10 | IL-2 | IFN-γ | IL-4 | IL-10 |
| 1 | − | + | − | − | 2±1 | 2±1 | 4±1 | 2±1 | ||||||
| 2 | + | + | − | − | 1±1 | 1±1 | 9±1 | 3±1 | ||||||
| 3 | + | + | + | − | 11±4 | 388±54 | 67±11 | 26±7 | ||||||
| 4 | + | + | + | − | − | 10±3 | 328±128 | 27±5 | 22±4 | p=NS (#4 vs. #3) |
p=NS (#4 vs. #3) |
p=0.006 (#4 vs. #3) |
p=NS (#4 vs. #3) |
|
| 5 | + | + | + | − | − | + | 21±6 | 812±151 | 35±17 | 34±14 | p=NS (#5 vs. #3) |
p=0.03 (#5 vs. #3) |
p=NS (#5 vs. #3) |
p=NS (#5 vs. #3) |
| 6 | + | + | + | Th2 | − | − | 12±1 | 83±5 | 497±47 | 160±32 | p=NS (#6 vs. #3) |
p=0.0005 (#6 vs. #3) |
p<0.0001 (#6 vs. #3) |
p=0.003 (#6 vs. #3) |
| 7 | + | + | + | Th2 | − | − | 10±1 | 115±16 | 291±59 | 79±15 | p=NS; p=NS (#7 vs. #3); (#7 vs. #6) |
p=0.001; p=NS (#7 vs. #3); (#7 vs. #6) |
p=0.01;p=0.03 (#7 vs. #3); (#7 vs. #6) |
p=0.01;p=0.053 (#7 vs. #3); (#7 vs. #6) |
| 8 | + | + | + | Th2 | − | + | 35±17 | 279±33 | 217±96 | 51±22 | p=NS ; p=NS (#8 vs. #3); (#8 vs. #6) |
p=NS ; p=0.0004 (#8 vs. #3); (#8 vs. #6) |
p=NS; p=0.03 (#8 vs. #3); (#8 vs. #6) |
p=NS; p=NS (#8 vs. #3); (#8 vs. #6) |
a
BALB/c host received 850 cGy XRT; host TS/A tumor cells 0.1× 106.
b
C57BL/6 into BALB/c (day 0); BM (C57BL/6; 10×106 cells); donor T cells (5×106 cells); donor Th2 cells (10×106 cells; day 14 post-BMT).
c
Fresh DC cells generated from donor C57BL/6 (10×106 cells; day14 post-BMT).
d
Fresh DC cells generated from host BALB/c (10×106 cells; day14 post-BMT).
e
Cytokine production measured by Luminex assay at day19 post-BMT; IL-4, IL-10, IL-2, and IFN-γ (pg/ml); Mean ± SEM of n=5/group.
f
Unpaired t test.